Navigation Links
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
Date:5/27/2009

invaluable, and we can now incorporate these insights in a follow-on clinical trial that we are planning to initiate later this year. Our goal remains to significantly improve the symptoms of Parkinson's patients and also to provide the opportunity to delay further disease progression."

About Phase 2 Trial of CERE-120

Ceregene's Phase 2 trial was a double-blind, controlled clinical trial that completed enrollment of 58 patients with advanced Parkinson's disease in October 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in the Phase 2 trial were enrolled across nine leading academic medical centers in the United States, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for a minimum of 12 months for safety and efficacy, with over half the subjects followed for 15 to 18 months under blinded conditions, allowing longer-term analyses of the therapeutic effects of CERE-120. Ceregene gratefully acknowledges the financial support received from the Michael J. Fox Foundation for Parkinson's Research to help defray some of the costs of the CERE-120 Phase 1 and Phase 2 clinical trials.

About CERE-120 and its Application to Treating Parkinson's Disease

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function. Neurturin is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharm
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
2. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
5. Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
6. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
7. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
8. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
9. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
10. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
11. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 LunaDress, with its top dressmaking technologies, ... Now, the business is showing its latest designs of wedding ... According to the company’s CEO, all the fresh new products ... big discounts, up to 80% off. All the clothes from ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... in Germany, soccer fans can now rest assured that women ... to a new study by researchers at Wake Forest Baptist ... Research in Sports Medicine. , "Injuries are common in ... the international level," said Daryl Rosenbaum, M.D., an assistant professor ...
... WEDNESDAY, July 6 (HealthDay News) -- Simpler and shorter ... in millions of people worldwide infected with the bacterium ... researchers report. TB, or tuberculosis, is the leading ... virus that causes AIDS. About half a million people ...
... social media fans to comment in 140 characters or less ... tragic toll or the great taste of a grilled cheese ... of banter, is it possible to also track important public ... with a one-word tweet: "Yes!" Mark Dredze and Michael ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, July 6 ... steak or a hot fudge sundae, consider this: The high you ... one you might feel if you smoked marijuana. The ... is, a nearly irresistible desire to eat -- appears to help ...
... Top-performing hospitals are typically ones headed by a medical doctor rather ... study of what makes a good hospital. The research, to ... , is the first of its kind. Its conclusions run ... generally trained managers -- not those with a medical degree -- ...
... , WEDNESDAY, July 6 (HealthDay News) -- Men are ... a noisy setting, a talent that may have developed through evolution, ... women by having them listen to sounds and determine the location ... at a time, and both men and women had high levels ...
Cached Medicine News:Health News:New study: Women less likely than men to fake soccer injuries 2Health News:New Combo Therapy May Prevent TB, Save Lives in People With HIV 2Health News:You are what you tweet: Tracking public health trends with Twitter 2Health News:You are what you tweet: Tracking public health trends with Twitter 3Health News:Binge Eating May Be a High All Its Own 2Health News:Binge Eating May Be a High All Its Own 3Health News:The best hospitals are run by physicians 2
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Roper Industries, Inc.   (NYSE: ... 2009, ended December 31, 2009 , will be released before the ... to discuss these results has been scheduled for 8:30 AM ET ... accessed via webcast or by dialing +1 888-539-3679 (US/ Canada ) or ...
... SAN DIEGO , Jan. 20 First Coast ... to treat breast cancer with the addition of a Naviscan PEM ... in the nation to use both a PEM scanner and the ... , AccuBoost is a technique for whole breast irradiation that is ...
Cached Medicine Technology:First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment 2First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment 3
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, semi-sharp, wedge shaped inferior edge with a pointed tip, dual sideports, 20 gauge. For Phakonit cataract surgery....
Phaco chopper elongated Kuglen style push-pull tip with wedge shaped superior and inferior edges. For bi-directional chopping....
Medicine Products: